Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)

NCT04555096 is registered in ClinicalTrials.gov with Galera Therapeutics, Inc. as lead sponsor.

NCT NCT04555096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04555096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)
Lead sponsor
Galera Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 9, 2020
Completion date
May 28, 2021
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars-cov-2 infection